PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 84 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2013. The put-call ratio across all filers is 4.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $27,817,000 | +53.7% | 3,219,577 | +12.6% | 0.01% | +25.0% |
Q3 2016 | $18,098,000 | +57.7% | 2,859,154 | +5.1% | 0.00% | +33.3% |
Q2 2016 | $11,477,000 | -3.4% | 2,719,685 | -0.2% | 0.00% | 0.0% |
Q1 2016 | $11,884,000 | -28.3% | 2,725,796 | +0.8% | 0.00% | -25.0% |
Q4 2015 | $16,580,000 | +2.1% | 2,704,794 | -4.8% | 0.00% | 0.0% |
Q3 2015 | $16,245,000 | -20.5% | 2,840,096 | +3.6% | 0.00% | -20.0% |
Q2 2015 | $20,442,000 | +22.4% | 2,740,154 | -1.9% | 0.01% | +25.0% |
Q1 2015 | $16,705,000 | -19.5% | 2,793,406 | +1.8% | 0.00% | -20.0% |
Q4 2014 | $20,753,000 | +58.9% | 2,745,169 | +9.1% | 0.01% | +25.0% |
Q3 2014 | $13,063,000 | +16.8% | 2,516,967 | -3.0% | 0.00% | +33.3% |
Q2 2014 | $11,184,000 | -1.0% | 2,594,840 | -6.0% | 0.00% | 0.0% |
Q1 2014 | $11,294,000 | -9.2% | 2,761,329 | +18.4% | 0.00% | -25.0% |
Q4 2013 | $12,435,000 | +4.4% | 2,332,965 | -1.7% | 0.00% | 0.0% |
Q3 2013 | $11,915,000 | +54.5% | 2,373,556 | +37.3% | 0.00% | +33.3% |
Q2 2013 | $7,711,000 | – | 1,729,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |